Enanta Pharmaceuticals (ENTA)Deep Track Capital, LP opened a new position $30.9M

1.96M

Shares reported

0.55%

Disclosed portfolio weight

$30.9M

Reported value

Holdings as of

Dec 31, 2025

Filed

Feb 13, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Feb 9, 2026Company filing · Form 8-K · ResultsReported its results

What came next

1. Mar 11, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“As disclosed below under Item 5.07, on March 11, 2026, the stockholders of Enanta Pharmaceuticals, Inc. approved an amendment to its 2019 Equity Incentive Plan to increase the number of shares reserved for issuance thereunder by 1,600,000 shares.”
2. May 11, 2026Company filing · Form 8-K · ResultsReported its results

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Enanta Pharmaceuticals

For Enanta Pharmaceuticals, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ENTA page.

How this filing works

• SEC Form 13F

Other disclosures at Enanta Pharmaceuticals

• SEC Form 13F-HRAug 14, 2026
• SEC Form 4Dec 5, 2025
• SEC Form 4Dec 5, 2025
• SEC Form 4Dec 5, 2025
• SEC Form 4Dec 5, 2025
• SEC Form 4Dec 5, 2025

Everything OQRO holds on this company is on its ENTA page.